B Denis1, M Lafaurie2, J-L Donay3, J-P Fontaine4, E Oksenhendler5, E Raffoux6, C Hennequin7, M Allez8, G Socie9, N Maziers10, R Porcher11, J-M Molina2. 1. Department of Infectious Diseases, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, 75010, Paris, France; Inserm UMRS 1136, UPMC Université Paris 06, Paris, France. Electronic address: blandine.denis@sls.aphp.fr. 2. Department of Infectious Diseases, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, 75010, Paris, France. 3. Department of Microbiology, Hôpital Saint-Louis, AP-HP, Paris, France. 4. Emergency Department, Hôpital Saint-Louis, AP-HP, Paris, France. 5. Department of Clinical Immunology, Hôpital Saint-Louis, AP-HP, Paris, France. 6. Department of Haematology, Hôpital Saint-Louis, AP-HP, Paris, France. 7. Department of Oncology, Hôpital Saint-Louis, AP-HP, Paris, France. 8. Department of Gastroenterology, Hôpital Saint-Louis, AP-HP, Paris, France. 9. Department of Haematology-Bone Marrow Transplantation, Hôpital Saint-Louis, AP-HP, Paris, France. 10. Department of Intensive Care, Hôpital Saint-Louis, AP-HP, Paris, France. 11. Department of Biomedical Statistics and Methodology, Hôpital Saint-Louis, AP-HP, Paris, France.
Abstract
BACKGROUND: The impact of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) bacteraemia on outcome remains controversial. METHODS: A retrospective analysis of the prevalence, risk factors, clinical features, and outcomes of all ESBL-EC bacteraemia in one French hospital over a 5-year period was performed. A case-control study was undertaken: cases had at least one ESBL-EC bacteraemia and controls a positive non-ESBL-EC bacteraemia. RESULTS: The prevalence of ESBL-EC bacteraemia increased from 5.2% of all positive E. coli blood cultures in 2005 to 13.5% in 2009 (p<0.003). CTX-M represented 70% of ESBL-EC bacteraemia strains, and strains were not clonally related. On adjusted analysis, the only significant risk factor for ESBL-EC bacteraemia was a previous ESBL-EC colonization (odds ratio 11.3, 95% confidence interval 1.2-107; p=0.003). Initial antimicrobial therapy was less frequently adequate in the ESBL-EC group (48% vs. 85%; p=0.003). The presence of ESBL-EC bacteraemia was not associated with a longer hospital stay (p=0.088). Day 30 mortality was high, but not significantly different in the two groups (30% vs. 27%; p=0. 82). CONCLUSION: The prevalence of ESBL-EC bacteraemia has been increasing dramatically. Previous colonization with ESBL-EC was a strong risk factor for ESBL-EC bacteraemia. More inadequate initial antimicrobial therapy was noted in the ESBL-EC group, but mortality and length of hospital stay were not significantly different from those of patients with non-ESBL-EC bacteraemia.
BACKGROUND: The impact of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) bacteraemia on outcome remains controversial. METHODS: A retrospective analysis of the prevalence, risk factors, clinical features, and outcomes of all ESBL-EC bacteraemia in one French hospital over a 5-year period was performed. A case-control study was undertaken: cases had at least one ESBL-EC bacteraemia and controls a positive non-ESBL-EC bacteraemia. RESULTS: The prevalence of ESBL-EC bacteraemia increased from 5.2% of all positive E. coli blood cultures in 2005 to 13.5% in 2009 (p<0.003). CTX-M represented 70% of ESBL-EC bacteraemia strains, and strains were not clonally related. On adjusted analysis, the only significant risk factor for ESBL-EC bacteraemia was a previous ESBL-EC colonization (odds ratio 11.3, 95% confidence interval 1.2-107; p=0.003). Initial antimicrobial therapy was less frequently adequate in the ESBL-EC group (48% vs. 85%; p=0.003). The presence of ESBL-EC bacteraemia was not associated with a longer hospital stay (p=0.088). Day 30 mortality was high, but not significantly different in the two groups (30% vs. 27%; p=0. 82). CONCLUSION: The prevalence of ESBL-EC bacteraemia has been increasing dramatically. Previous colonization with ESBL-EC was a strong risk factor for ESBL-EC bacteraemia. More inadequate initial antimicrobial therapy was noted in the ESBL-EC group, but mortality and length of hospital stay were not significantly different from those of patients with non-ESBL-EC bacteraemia.
Authors: Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: T A V Hoang; T N H Nguyen; S Ueda; Q P Le; T T N Tran; T N D Nguyen; T V K Dao; M T Tran; T T T Le; T L Le; T Nakayama; I Hirai; T H Do; Q M Vien; Y Yamamoto Journal: Curr Microbiol Date: 2016-12-09 Impact factor: 2.188
Authors: Juan González Del Castillo; Agustín Julián-Jiménez; Julio Javier Gamazo-Del Rio; Eric Jorge García-Lamberechts; Ferrán Llopis-Roca; Josep María Guardiola Tey; Mikel Martínez-Ortiz de Zarate; Carmen Navarro Bustos; Pascual Piñera Salmerón; Jesús Álvarez-Manzanares; María Del Mar Ortega Romero; Martin Ruiz Grinspan; Susana García Gutiérrez; Francisco Javier Martín-Sánchez; Francisco Javier Candel González Journal: Eur J Clin Microbiol Infect Dis Date: 2019-11-13 Impact factor: 3.267
Authors: L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-08 Impact factor: 3.267
Authors: Kathryn L McDonald; Sarah Garland; Carolee A Carson; Kimberly Gibbens; E Jane Parmley; Rita Finley; Melissa C MacKinnon Journal: JAC Antimicrob Resist Date: 2021-02-14